Program and platform directors

With nearly a decade of experience in biological sample management, Kristin Ardlie is the director of the Broad Institute’s Biological Samples Platform. She is a leader in scientific technologies for ensuring sample quality, accuracy, and integrity for genome-scale research.

A leader in state-of-the art methods for large-scale DNA sequencing, Jennifer Baldwin serves as director of the Broad Institute’s Genome Sequencing Platform. She oversees and manages all aspects of the institute’s high-throughput DNA sequencing facility, from production and finishing to informatics and project management.

An expert in genomic mapping, sequencing, and analysis, Bruce Birren co-directs the Broad’s Genome Sequencing and Analysis Program. He is leading efforts to decode the genomes of a variety of fungi as well as microbes, including bacteria, viruses, parasites, and insect vectors of disease.

With expertise in cell biology, microscopy, and computational biology, Anne Carpenter is the director of the Broad Institute’s Imaging Platform. She is leading efforts to develop and apply high-throughput methods for analyzing biological images.

An expert in protein chemistry and technology, Steven Carr leads the Broad Institute’s Proteomics Platform. He is guiding the development and application of sophisticated proteomic methods to characterize proteins, their roles in normal biology and disease, and interactions with drugs.

A leader in chemistry and chemical technology, Mike Foley serves as director of the Chemical Biology Platform at the Broad Institute. He leads the design and synthesis of the institute’s diverse collection of chemical compounds, in addition to guiding its high-throughput chemical screening efforts.

The Broad Institute’s Genetic Analysis Platform is led by Stacey Gabriel, who brings significant expertise in genotyping and other human genetics technologies to her position as platform director. She oversees all genotyping, SNP discovery, and production activities related to human genetics at the Institute.

With extensive expertise in drug discovery and development, Robert Gould is the director of the new Novel Therapeutics Platform at the Broad Institute. He is leading an effort to integrate and apply innovative genomic and chemical biology methods to overcome key challenges in drug discovery.

With more than a decade of experience in large-scale sequencing, Chad Nusbaum serves as co-director of the Broad’s Genome Sequencing and Analysis Program. He oversees the development, implementation, and application of new DNA sequencing technologies and also leads several microbial and fungal genome projects.

With expertise in physical chemistry, David Root serves as director of the RNA interference (RNAi) Platform at the Broad Institute. He is leading the large-scale development and implementation of state-of-the-art RNAi tools for biomedical research.